Edinburgh Napier's software development security spinout has been acquired by strategic partner Ping Identity.

The MIT cell therapy spinout priced its shares at the bottom of their range to raise $70.6m, following some $166m in venture funding.

Genetic testing company Prenetics leveraged a UK-based subsidiary to buy Oxsed having piloted the latter's rapid coronavirus screening system.

Intel is set to buy Stanford University-backed machine learning optimisation business SigOpt, which had raised at least $8.6m in funding.

Spun out of University of Louisville, Koligo Therapeutics has already launched its first cell therapy product and aims to commercialise a treatment for covid-19.

Novartis has bought Vedere Bio, a retinal disease therapy spinout of UC Berkeley also exploiting UPenn research, to expand its gene medicine capabilities.

Exact Sciences has shelled out $410m to buy University of Oxford early cancer test company Base Genomics, incorporated in July 2019.

Exact Sciences is set to acquire Johns Hopkins spinout Thrive Earlier Detection for up to $2.15bn in cash and stock, including $1.7bn upfront.

University of Toronto's FPGA programming platform developer LegUp Computing has been acquired in a deal that allowed Intel Capital to exit.

Aalto's bone lengthening treatment spinout Synoste has been snapped up after raising funding from investors including Evonik and Mectalent.